A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)
Clinical trial NCT03594058 · COMPLETED
Trial details
- NCT number
- NCT03594058
- Sponsor
- Velicept Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-07-09
- Primary completion
- 2019-04-29
- Enrollment
- 1413
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.